Guardant Health/$GH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Guardant Health
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Ticker
$GH
Sector
Primary listing
Industry
Health Care Providers & Services
Headquarters
Employees
2,010
ISIN
US40131M1099
Website
Guardant Health Metrics
BasicAdvanced
$6.2B
-
-$3.38
1.45
-
Price and volume
Market cap
$6.2B
Beta
1.45
52-week high
$53.42
52-week low
$20.14
Average daily volume
2.2M
Financial strength
Current ratio
4.106
Quick ratio
3.606
Long term debt to equity
-509.08
Total debt to equity
-520.909
Interest coverage (TTM)
-166.70%
Profitability
EBITDA (TTM)
-413.046
Gross margin (TTM)
61.34%
Net profit margin (TTM)
-53.82%
Operating margin (TTM)
-58.73%
Effective tax rate (TTM)
-0.28%
Revenue per employee (TTM)
$390,000
Management effectiveness
Return on assets (TTM)
-18.65%
Return on equity (TTM)
456.48%
Valuation
Price to revenue (TTM)
7.928
Price to book
-24.54
Price to tangible book (TTM)
-23.64
Price to free cash flow (TTM)
-20.126
Free cash flow yield (TTM)
-4.97%
Free cash flow per share (TTM)
-247.29%
Growth
Revenue change (TTM)
28.20%
Earnings per share change (TTM)
-14.41%
3-year revenue growth (CAGR)
25.55%
3-year earnings per share growth (CAGR)
-6.47%
What the Analysts think about Guardant Health
Analyst ratings (Buy, Hold, Sell) for Guardant Health stock.
Bulls say / Bears say
The FDA granted Breakthrough Device designation to Guardant Health's Shield multi-cancer detection test, potentially accelerating its market entry and enhancing the company's competitive edge. (nasdaq.com)
Guardant Health secured a $90.7 million investment from Baillie Gifford, indicating strong institutional confidence and providing capital for expansion and innovation. (biospace.com)
Time magazine recognized Guardant's Shield product as one of the top innovations of 2024, highlighting its impact in colorectal cancer diagnostics and boosting the company's reputation. (nasdaq.com)
Barclays reduced its price target for Guardant Health to $55.00, suggesting potential concerns about the company's future performance. (etfdailynews.com)
Insider selling activity, including Director Musa Tariq's sale of 2,320 shares, may indicate a lack of confidence among company executives. (marketbeat.com)
Despite positive developments, Guardant Health reported a net loss in its latest earnings, raising concerns about its path to profitability. (marketbeat.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
Guardant Health Financial Performance
Revenues and expenses
Guardant Health Earnings Performance
Company profitability
Guardant Health News
AllArticlesVideos
Medical Services Name Flirts With A Buy Point
Investors Business Daily·3 weeks ago
Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening
Business Wire·1 month ago
New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Guardant Health stock?
Guardant Health (GH) has a market cap of $6.2B as of July 15, 2025.
What is the P/E ratio for Guardant Health stock?
The price to earnings (P/E) ratio for Guardant Health (GH) stock is 0 as of July 15, 2025.
Does Guardant Health stock pay dividends?
No, Guardant Health (GH) stock does not pay dividends to its shareholders as of July 15, 2025.
When is the next Guardant Health dividend payment date?
Guardant Health (GH) stock does not pay dividends to its shareholders.
What is the beta indicator for Guardant Health?
Guardant Health (GH) has a beta rating of 1.45. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.